VivoSeq
Other

Pilot Study

0

Pipeline Programs

26

Active Trials

34

Companies Involved

Pilot Study is an early-stage landscape with 0 programs across 34 companies. The most active players are GSK, Oxford Pharmascience Ltd, Orion Corporation, Orion Pharma.

Pipeline Metrics

Competitive Density

39/100

Pipeline Velocity

19/100

Mech. Concentration

N/A

Completion Rate

80/100

Attrition Rate

17/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

333

clinical trials

Completed223 · 67%
Terminated35 · 11%
Unknown status29 · 9%
Withdrawn20 · 6%
Recruiting14 · 4%
Active, not recruiting6 · 2%
Other6 · 2%

Trial Activity

333 trials

Pilot Study of Reduced Venetoclax Exposure
Recruiting·NNorthwell Health·Phase 2·NCT07163793·41 enrolled
Pilot Study of RR-HNK in OCD
Recruiting··Phase 1/2·NCT06575075·45 enrolled
Page 1 of 23

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)